{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T13:49:03Z","timestamp":1775915343338,"version":"3.50.1"},"reference-count":10,"publisher":"American Society of Hematology","issue":"25","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,20]]},"DOI":"10.1182\/blood.2024024709","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:31:02Z","timestamp":1718897462000},"page":"2564-2565","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenic therapy: new actors in myeloma"],"prefix":"10.1182","volume":"143","author":[{"given":"Antonio G.","family":"Solimando","sequence":"first","affiliation":[{"name":"University of Bari Aldo Moro Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Vacca","sequence":"additional","affiliation":[{"name":"University of Bari Aldo Moro Medical School"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"25","key":"2024062015305656500_bib1","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood.2023022777","article-title":"Loss\u00a0of\u00a0GABARAP mediates resistance to\u00a0immunogenic chemotherapy in multiple\u00a0myeloma","volume":"143","author":"Gulla","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2024062015305656500_bib2","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41590-022-01132-2","article-title":"Immunogenic cell stress and death","volume":"23","author":"Kroemer","year":"2022","journal-title":"Nat Immunol"},{"issue":"1","key":"2024062015305656500_bib3","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nm1523","article-title":"Calreticulin exposure dictates the immunogenicity of cancer cell death","volume":"13","author":"Obeid","year":"2007","journal-title":"Nat Med"},{"issue":"11","key":"2024062015305656500_bib4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis"},{"issue":"5","key":"2024062015305656500_bib5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1158\/2643-3230.BCD-21-0047","article-title":"Bortezomib induces anti-multiple myeloma immune response mediated by cGAS\/STING pathway activation","volume":"2","author":"Gulla","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"12","key":"2024062015305656500_bib6","doi-asserted-by":"crossref","first-page":"3961","DOI":"10.1096\/fj.201600698R","article-title":"LC3\/GABARAP family proteins: autophagy-(un)related functions","volume":"30","author":"Schaaf","year":"2016","journal-title":"FASEB J"},{"issue":"4","key":"2024062015305656500_bib7","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17474086.2021.1909469","article-title":"A\u00a0new decade: novel immunotherapies on the horizon for relapsed\/refractory multiple myeloma","volume":"14","author":"Braunstein","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"9","key":"2024062015305656500_bib8","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1182\/blood-2014-11-612069","article-title":"Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and\/or translocation (4;14): IFM 2010-02 trial results","volume":"125","author":"Leleu","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2024062015305656500_bib9","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.ccell.2022.10.017","article-title":"Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma","volume":"40","author":"Sklavenitis-Pistofidis","year":"2022","journal-title":"Cancer Cell"},{"issue":"3","key":"2024062015305656500_bib10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2010.223","article-title":"Immune parameters affecting the efficacy of chemotherapeutic regimens","volume":"8","author":"Zitvogel","year":"2011","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/25\/2564\/2230203\/blood_bld-2024-024709-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/143\/25\/2564\/2230203\/blood_bld-2024-024709-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T15:31:10Z","timestamp":1718897470000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/143\/25\/2564\/516473\/Immunogenic-therapy-new-actors-in-myeloma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":10,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2024,6,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024024709","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}